| Under the terms of the agreement, Shasun Pharma grants H Lundbeck A/S the use of its proprietary cross-coupling technology (also known as Buchwald technology) to manufacture and commercialize new APIs (Active Pharmaceutical Ingredients). The Buchwald cross-coupling technology is one of the most referred to technologies in the pharmaceutical area allowing increasing complex new drugs to be manufactured in a more straightforward and economical way. |
| Commenting on the development, Dr. Michel Spagnol, Vice President, Lundbeck said, "Lundbeck will have access to one of the most powerful cross-coupling technologies allowing them to speed up the development of new drugs while reducing the cost of manufacture." |
| Mr. Govindarajan, CEO and MD of Shasun Chemicals & Drugs added, "This is yet another example of Shasun's flexibility in dealing with the management of its Intellectual Property and making sure that it services its customer first!" |
| About Shasun Chemicals & Drugs Ltd: Shasun Chemicals and Drugs Ltd., India is a premier service provider to the pharmaceutical industry. It was founded in 1976 and its headquarters are in Chennai, Tamilnadu, India. With the maiden acquisition of business and assets of UK-based Rhodia Pharma through the wholly owned subsidiary Shasun Pharma Solutions Ltd (SPSL), Shasun has now become a multi national company. For further information, please visit: https://bsmedia.business-standard.comshasun.com/ |
| About H Lundbeck A/S: H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit MailScanner has detected a possible fraud attempt from ".." claiming to be www.lundbeck.com |
Top Section
Explore Business Standard